Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate) (1) ·
Lantus, Basaglar, Semglee, Toujeo (U-300) (1) ·
Lipitor (1) ·
Lotensin (1) ·
Micardis (1) ·
Pravachol (1) ·
Tresiba (1) ·
Zestril, Prinivil, Qbrelis (1)
classes:
Androgen / Anabolic Steroid (1) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (2) ·
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (3) ·
[[:Category:Basal_insulins|Basal insulin]] (2) ·
[[:Category:Insulins|Insulin]] (2) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (2) ·
[[:Category:Long-acting_insulins|Long-acting insulin analog]] (1) ·
[[:Category:Statins|Statin]] (2) ·
[[:Category:Ultra-long-acting_insulins|Ultra-long-acting insulin analog]] (1)
mechanism:
None (1) ·
Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT. (1) ·
'"`UNIQ--vote-00000053-QINU`"' Also raises bradykinin, contributing to vasodilation and the characteristic dry cough. Renally cleared, unmetabolized; dose-adjust by eGFR'"`UNIQ--ref-00000054-QINU`"'. (1) ·
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) ·
'"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1) ·
'"`UNIQ--vote-00000A1D-QINU`"' Like other ACE inhibitors, it raises bradykinin (driving the dry cough and rare angioedema). Renally cleared; dose-adjust in renal impairment'"`UNIQ--ref-00000A1E-QINU`"'. (1) ·
'"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1) ·
'"`UNIQ--vote-00001356-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio'"`UNIQ--ref-00001357-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"' (1) ·
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"' (1) ·
'"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"' (1) ·
'"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"' (1) ·
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1) ·
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1)
starting dose:
10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) ·
10-20 mg PO once daily (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) ·
40 mg PO once daily; titrate to 80 mg (1) ·
5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1) ·
Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d. (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2)
preparations:
10 mg, 20 mg, 40 mg, 80 mg tablets (2) ·
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) ·
20, 40, 80 mg tablets (1) ·
5, 10, 20, 40 mg tablets (1) ·
Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets (1)
fda max: (Click arrow to add another value)
routes:
onset:
1-2 hours (1) ·
BP effect within 1-2 weeks (1) ·
BP lowering within 1 hour; max at 6 hours (1) ·
BP lowering within 1 hour; max effect at 6 hours (1) ·
Hours (transdermal); days (IM esters) (1) ·
LDL lowering at 2 weeks, max by 4 weeks (1) ·
LDL lowering at 2 weeks, max by 4 weeks; cardiovascular benefit months to years (1) ·
~1 hour (1)
duration:
halflife:
10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' (1) ·
14 hours (parent); 20-30 hours including active ortho- and para-hydroxylated metabolites'"`UNIQ--ref-0000001B-QINU`"' (1) ·
Highly variable by formulation; native T is hours (1) ·
~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"' (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) ·
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1)
bioavailability:
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) ·
Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) (1) ·
~100% from subcutaneous depot (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) ·
~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-0000005B-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000A24-QINU`"' (1) ·
Category X, contraindicated; teratogenic (virilization of female fetus) (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized; lactation generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 8 results in range #1 to #8.